Success	PI/ Award Year	Publication
Cancer Treatments		
Treatment options for epithelial cancers by developing strategies for therapeutic immune radiotherapy delivering radioactivity directed specifically to tumors and tumor cells	Pastan, I. 1999	Pai-Scherf, Lee H., et al. "Imaging and phase I study of 111In-and 90Y-labeled anti-LewisY monoclonal antibody B3." *Clinical Cancer Research* 6.5 (2000): 1720-1730
Small lymphocytic lymphoma (SLL)/Chronic lymphocytic leukemia (CLL) therapy by developing approaches of anti-CD20 mAbs that preserve CD20 cell-surface expression on CLL cells which have led to new Rituximab-based combinations, novel schedules, and the design of the next generation of antibodies	Weistner, A. 2007	Aue, Georg, et al. "Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia." *Haematologica* 95.2 (2010): 329-332
AIDS Treatments		
Eliminating HIV-1 reservoirs using combination of intense treatment and immune intervention to eliminate activated latently infected cells	Maldarelli, F. 2008	Maldarelli, Frank. "Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication." *Current Opinion in HIV and AIDS* 6.1 (2011): 49-56
Understanding the interactions between hemolysis and infectious vasculopathy which modified the prevalence, age of onset, and severity of pulmonary hypertension among sickle cell patients	Ognibene, F. 2001	Gladwin, Mark T., et al. "Pulmonary hypertension as a risk factor for death in patients with sickle cell disease." *New England Journal of Medicine* 350.9 (2004): 886-895
Rare Diseases		
BtB support enabled identification of biomarkers (patent #US 20090286272 A1) and laid the groundwork for a Phase I clinical trial to evaluate the safety and effectiveness of cyclodextrin as a potential therapy for Niemann-Pick type C1. Additionally, the collaboration established by two BtB awards led the team to successfully apply for a U01 award, "A Phase 1 Dose Escalation Study of Vorinostat in Niemann-Pick C1 Disease"	Porter, F. 2010 &2011	Cluzeau, Celine VM, et al. "Microarray expression analysis and identification of serum biomarkers for Niemann–Pick disease, type C1." *Human Molecular Genetics* (2012): dds193
Signaling Molecules and Genetic Disorders		
Lysosomal storage Disorder and Infantile Neuronal ceroid lipofuscinoses (INCLs) studies resulted in identifying Cysteamine Bitartate (Cystagon) as a potential target that could stop the progression of retinal and brain damage in infants with INCL.	Mukherjee, A. 2000.	Miao, Ning, et al. "Children with infantile neuronal ceroid lipofuscinosis have an increased risk of hypothermia and bradycardia during anesthesia." *Anesthesia and Analgesia* 109.2 (2009): 372
Hutchinson-Gilford Progeria Syndrome (HGPS) and the use of Farnesyl Transferase inhibitors was investigated and showed a potential approach to tackle this disorder's effects on body weight, fat tissue and bone mineralization, and fracture rate.	Gordon, L. 2005	Merideth, Melissa A., et al. "Phenotype and course of Hutchinson–Gilford progeria syndrome." *New England Journal of Medicine* 358.6 (2008): 592-604